Physician profile
Daniel White
NPI 1124603758
$7,507.19
in general payments reported to CMS, 2019-2025
11 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 95% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.79 · 2022: $4,145 · 2023: $598 · 2024: $953 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028 · Travel and Lodging: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.03 |
| Travel and Lodging | $281.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,396.36 | 2022-2023 | |
| Stryker Corporation | $2,454.30 | 2023-2025 | Mako, Triathlon |
| Seapearl East, INC | $789.03 | 2022 | |
| Depuy Synthes Sales INC. | $404.04 | 2023-2024 | Actis, Monovisc |
| Globus Medical, INC. | $186.52 | 2021-2023 | Providence |
| Si-Bone, INC. | $97.09 | 2024 | |
| Davol INC. | $90.45 | 2023 | Arista Ah Flexitip |
| Becton, Dickinson and Company | $35.53 | 2024 | Channel Drain |
| Heraeus Medical, LLC. | $19.25 | 2024 | |
| Ibsa Pharma INC. | $18.62 | 2023 | Tirosint, Licart |
| Collegium Pharmaceutical, INC. | $16.00 | 2024 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.